Get the Stockscreener App
1.63
10.14%
0.15
After Hours:
1.61
-0.02
-1.23%
Invivyd Inc stock is traded at $1.63, with a volume of 3.83M.
It is up +10.14% in the last 24 hours and down -35.32% over the past month.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
See More
Previous Close:
$1.48
Open:
$1.46
24h Volume:
3.83M
Relative Volume:
0.60
Market Cap:
$459.64M
Revenue:
-
Net Income/Loss:
$-225.14M
P/E Ratio:
-0.8316
EPS:
-1.96
Net Cash Flow:
$-192.27M
1W Performance:
-13.30%
1M Performance:
-35.32%
6M Performance:
+104.29%
1Y Performance:
+3.82%
1-Day Range:
$1.46
$1.645
1-Week Range:
$1.46
$1.957
52-Week Range:
$0.46
$3.0699
Invivyd Inc Stock (IVVD) Company Profile
Name
Invivyd Inc
Sector
Industry
Phone
(781) 819-0080
Address
209 CHURCH STREET, NEW HAVEN
Compare IVVD vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
1.63 | 417.34M | 0 | -225.14M | -192.27M | -1.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.48 | 119.47B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.91 | 82.49B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.16 | 51.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.98 | 42.28B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
353.43 | 38.60B | 4.98B | 69.60M | 525.67M | 0.5198 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-22-25 | Initiated | BTIG Research | Buy |
| Nov-25-25 | Downgrade | D. Boral Capital | Buy → Hold |
| Oct-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-05-24 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-26-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-19-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| May-01-23 | Initiated | H.C. Wainwright | Buy |
View All
Invivyd Inc Stock (IVVD) Latest News
Invivyd, Inc. (NASDAQ:IVVD) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Invivyd prices $125M stock offering at $2.50 per share - MSN
Analysts Offer Insights on Healthcare Companies: Invivyd (IVVD) and Pfizer (PFE) - The Globe and Mail
H.C. Wainwright reiterates Buy rating on Invivyd stock amid FDA feedback - Investing.com Nigeria
Invivyd receives FDA feedback on COVID antibody vs mRNA vaccine trial - Investing.com Nigeria
Invivyd receives FDA feedback on COVID antibody vs mRNA vaccine trial By Investing.com - Investing.com South Africa
Invivyd rises as FDA agrees with late-stage trial design for COVID-19 therapy - Seeking Alpha
Invivyd aligns with FDA for Phase 3 vaccine trial - Traders Union
Invivyd rises on late-stage trial testing COVID antibody against mRNA vaccines - TradingView
Invivyd, Inc. Announces FDA Alignment on LIBERTY Phase 3 Clinical Trial for VYD2311, a Monoclonal Antibody Candidate for COVID-19 Prevention - Quiver Quantitative
Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration - The Manila Times
Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 ... - Caledonian Record
FDA asks Invivyd to track myocarditis in new COVID antibody vs vaccine trial - Stock Titan
Invivyd Reports Strong Q3 Growth and Strategic Advances - MSN
Invivyd, Inc. (NASDAQ:IVVD) Short Interest Update - MarketBeat
Invivyd, Inc.'s (NASDAQ:IVVD) 26% Share Price Plunge Could Signal Some Risk - simplywall.st
Institutional investors in Invivyd, Inc. (NASDAQ:IVVD) see US$113m decrease in market cap last week, although long-term gains have benefitted them. - simplywall.st
Invivyd shares edge higher on education campaign with Olympic star Lindsey Vonn - MSN
HC Wainwright Predicts Invivyd FY2030 Earnings - MarketBeat
How Recent Price Target Resets Are Rewriting The Story For Invivyd (IVVD) - Yahoo Finance
H.C. Wainwright reaffirms Buy rating on Invivyd stock ahead of key trial data By Investing.com - Investing.com Nigeria
Aug Fed Impact: Should you avoid Invivyd Inc stock right now2025 Breakouts & Breakdowns & Consistent Growth Equity Picks - baoquankhu1.vn
H.C. Wainwright reaffirms Buy rating on Invivyd stock ahead of key trial data - Investing.com
Analysts Are Bullish on These Healthcare Stocks: Invivyd (IVVD), Alignment Healthcare (ALHC) - The Globe and Mail
Invivyd partners with ski champion Lindsey Vonn on antibody education By Investing.com - Investing.com Nigeria
Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates - sharewise.com
Invivyd partners with ski champion Lindsey Vonn on antibody education - Investing.com
Invivyd stock rises after partnering with Olympic champion Lindsey Vonn By Investing.com - Investing.com Canada
Invivyd partners with Lindsey Vonn to educate Americans on antibodies and disease prevention - marketscreener.com
Invivyd Announces Partnership with World Champion Skier - GlobeNewswire
Invivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention - Finviz
Invivyd stock maintains Buy rating at BTIG on Long COVID treatment potential - Investing.com UK
Invivyd stock maintains Buy rating at BTIG on Long COVID treatment potential By Investing.com - Investing.com Nigeria
Invivyd to begin phase 2 trial of antibody therapy for long COVID - Investing.com Nigeria
Invivyd to begin phase 2 trial of antibody therapy for long COVID By Investing.com - Investing.com South Africa
Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026 - The Manila Times
Invivyd Initiates Phase 2 Trial for VYD2311 Targeting Long COVID Patients - Intellectia AI
Experimental COVID antibody trial targets Long COVID and vaccine injury by 2026 - Stock Titan
Short Interest in Invivyd, Inc. (NASDAQ:IVVD) Grows By 24.4% - MarketBeat
Bull Run: What is the target price for Invivyd Inc stockMarket Volume Summary & Safe Entry Trade Reports - baoquankhu1.vn
Invivyd, Inc.'s (NASDAQ:IVVD) Business Is Trailing The Industry But Its Shares Aren't - 富途资讯
Invivyd, Inc. (NASDAQ:IVVD) Given Average Rating of "Hold" by Brokerages - MarketBeat
Invivyd (IVVD) Reports Strong Q4 Growth, Advances COVID Antibody to Phase 3 - Insider Monkey
Invivyd Inc Stock (IVVD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.36%
1.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):